Justin Paget/DigitalVision via Getty Images Johnson & Johnson's ( NYSE: JNJ ) seltorexant, a potentially first-in-class adjunctive treatment for depression, met primary and secondary endpoints in a phase 3 study in patients with co-occurring insomnia symptoms. Topline r esults showed that individuals on seltorexant saw a statistically significant improvement in depressive symptoms based on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at day 43, as well as improved sleep disturbance outcomes. These patients had failed previously on response to SSRI/SNRI antidepressants alone.
Seltorexant is considered a selective antagonist of the human orexin-2 receptor. Johnson & Johnson ( JNJ ) noted that ~60% of individuals on oral antidepressants experience residual insomnia symptoms. More on Johnson & Johnson Johnson & Johnson: Vital Signs Decent, A Compelling Value Case Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference (Transcript) J&J to buy eczema drug developer Yellow Jersey for over $1B ADHD diagnoses increasing, becoming an 'expanding public health concern': CDC.
